Back Hepatitis C

Hepatitis C

AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated

Hepatitis C treatment that leads to viral suppression significantly reduces the likelihood of liver disease progression and liver-related mortality, but most patients remain untreated, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC. Other studies found that a growing proportion of liver transplants are due to hepatocellular carcinoma, which can still occur even after treatment.

alt

AASLD 2013: Fixed-dose Sofosbuvir/Ledipasvir Cures Most Genotype 1 Hepatitis C

At least 95% of newly treated genotype 1 hepatitis C patients and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to findings from the LONESTAR study presented the 64th AASLD Liver Meeting last week in Washington, DC. While response rates were high overall, the 2 relapsers in the trial were not taking ribavirin.

alt

AASLD 2013: Viral Hepatitis Is a Leading Cause of Death Worldwide

The 2010 Global Burden of Disease Study -- the first to include underlying causes of deaths due to cirrhosis and liver cancer -- has identified chronic viral hepatitis as one of the leading causes of mortality worldwide, according to a presentation this week at the 64th AASLD Liver Meeting in Washington, DC. About 45% of liver cancer and 30% of cirrhosis is related to chronic hepatitis B, which is endemic in much of Asia and Africa, while chronic hepatitis C and alcohol use are each responsible for about 25% of deaths.

alt

AASLD 2013: Sofosbuvir + Ribavirin for 12 or 24 Weeks Cures Most Genotype 2-3 Hepatitis C Patients

A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of genotype 2 hepatitis C patients treated for 12 weeks and 85% of genotype 3 patients treated for 24 weeks, researchers reported last week at the 64th AASLD Liver Meeting in Washington, DC. A related study found that adding ribavirin to this combination may be an option for harder-to-treat individuals.

alt

AASLD 2013: Sofosbuvir Taken Before or After Liver Transplant Reduces HCV Recurrence

An interferon-free combination of sofosbuvir plus ribavirin administered before liver transplantation prevented hepatitis C recurrence in nearly two-thirds of patients, while the same regimen led to early viral clearance in three-quarters of those treated after transplantation, according to studies presented this week at the 64thAASLD Liver Meeting in Washington, DC.

alt

AASLD 2013: Daclatasvir + Asunaprevir Cures 85% of Genotype 1b Hepatitis C Patients in Japanese Study

An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response in 85% of Japanese patients with hepatitis C virus subtype 1b, according to findings presented at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

AASLD 2013: Merck Interferon-free Regimen Shows High Hepatitis C Cure Rate in Early Study

A 2-drug combination of direct-acting antivirals developed by Merck, MK-5172 and MK-8742, with or without ribavirin, achieved very high cure rates in patients with genotype 1 hepatitis C in a small study presented this week at the 64th AASLD Liver Meeting in Washington, DC.

alt

AASLD 2013: Simeprevir with Pegylated Interferon/ Ribavirin Cures Genotype 1 Hepatitis C in 80%

Simeprevir added to pegylated interferon and ribavirin performed well in difficult-to-treat treatment-naive patients and prior relapsers with genotype 1 chronic hepatitis C, according to 2 poster presentations at the 64th AASLD Liver Meeting last week in Washington, DC, as described in an announcement by Janssen.

alt

AASLD 2013: BMS Interferon-free Combo Cures Over 90% of Genotype 1 HCV in 12 Weeks

A combination of 3 direct-acting antivirals developed by Bristol-Myers Squibb --daclatasvir, asunaprevir, and BMS-791325 -- cured chronic hepatitis C virus (HCV) infection in over 90% of previously untreated patients in a mid-stage study, Gregory Everson from the University of Colorado reported this week at the 64thAASLD Liver Meeting in Washington, DC. The combination proved equally effective in people with genotype 1a and 1b HCV.

alt